uniQure (QURE) Competitors

$27.75 -1.42 (-4.87%)

Closing price 04:00 PM Eastern

Extended Trading

$27.63 -0.12 (-0.45%)

As of 04:46 PM Eastern

QURE vs. DNTH, INDV, LEGN, KNSA, and NNNN

Should you buy uniQure stock or one of its competitors? MarketBeat compares uniQure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with uniQure include Dianthus Therapeutics (DNTH), Indivior (INDV), Legend Biotech (LEGN), Kiniksa Pharmaceuticals International (KNSA), and Anbio Biotechnology (NNNN). These companies are all part of the "pharmaceutical products" industry.

How does uniQure compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 4.8% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Dianthus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, uniQure has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

uniQure has a net margin of -1,154.42% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
uniQure	-1,154.42%	-145.81%	-27.15%

In the previous week, Dianthus Therapeutics had 3 more articles in the media than uniQure. MarketBeat recorded 17 mentions for Dianthus Therapeutics and 14 mentions for uniQure. Dianthus Therapeutics' average media sentiment score of 1.12 beat uniQure's score of 0.52 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics currently has a consensus price target of $117.82, suggesting a potential upside of 37.25%. uniQure has a consensus price target of $42.83, suggesting a potential upside of 55.81%. Given uniQure's higher probable upside, analysts clearly believe uniQure is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Dianthus Therapeutics has higher earnings, but lower revenue than uniQure. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.34M	3,512.58	-$162.34M	-$4.13	N/A
uniQure	$18.09M	95.82	-$198.97M	-$3.48	N/A

Summary

Dianthus Therapeutics beats uniQure on 10 of the 17 factors compared between the two stocks.

How does uniQure compare to Indivior?

Indivior (NASDAQ:INDV) and uniQure (NASDAQ:QURE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

60.3% of Indivior shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 4.8% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Indivior has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, uniQure has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Indivior has a net margin of 19.44% compared to uniQure's net margin of -1,154.42%. uniQure's return on equity of -145.81% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
uniQure	-1,154.42%	-145.81%	-27.15%

In the previous week, uniQure had 7 more articles in the media than Indivior. MarketBeat recorded 14 mentions for uniQure and 7 mentions for Indivior. Indivior's average media sentiment score of 1.56 beat uniQure's score of 0.52 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
uniQure	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior presently has a consensus price target of $39.33, suggesting a potential upside of 3.67%. uniQure has a consensus price target of $42.83, suggesting a potential upside of 55.81%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53

Indivior has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.73	$210M	$1.95	19.46
uniQure	$18.09M	95.82	-$198.97M	-$3.48	N/A

Summary

Indivior beats uniQure on 10 of the 17 factors compared between the two stocks.

How does uniQure compare to Legend Biotech?

uniQure (NASDAQ:QURE) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

uniQure has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

uniQure has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$18.09M	95.82	-$198.97M	-$3.48	N/A
Legend Biotech	$1.03B	5.18	-$296.80M	-$0.80	N/A

uniQure currently has a consensus price target of $42.83, suggesting a potential upside of 55.81%. Legend Biotech has a consensus price target of $59.00, suggesting a potential upside of 104.88%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

78.8% of uniQure shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 4.8% of uniQure shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Legend Biotech has a net margin of -21.98% compared to uniQure's net margin of -1,154.42%. Legend Biotech's return on equity of -24.63% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Legend Biotech	-21.98%	-24.63%	-14.62%

In the previous week, uniQure had 2 more articles in the media than Legend Biotech. MarketBeat recorded 14 mentions for uniQure and 12 mentions for Legend Biotech. uniQure's average media sentiment score of 0.52 beat Legend Biotech's score of -0.36 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

uniQure and Legend Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does uniQure compare to Kiniksa Pharmaceuticals International?

uniQure (NASDAQ:QURE) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

uniQure has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

In the previous week, uniQure had 11 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 14 mentions for uniQure and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat uniQure's score of 0.52 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$18.09M	95.82	-$198.97M	-$3.48	N/A
Kiniksa Pharmaceuticals International	$677.56M	6.66	$59.01M	$0.90	65.12

uniQure currently has a consensus price target of $42.83, indicating a potential upside of 55.81%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, indicating a potential upside of 3.83%. Given uniQure's higher probable upside, analysts plainly believe uniQure is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Kiniksa Pharmaceuticals International	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to uniQure's net margin of -1,154.42%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

78.8% of uniQure shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 4.8% of uniQure shares are held by company insiders. Comparatively, 53.5% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Kiniksa Pharmaceuticals International beats uniQure on 10 of the 16 factors compared between the two stocks.

How does uniQure compare to Anbio Biotechnology?

uniQure (NASDAQ:QURE) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

78.8% of uniQure shares are held by institutional investors. 4.8% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

uniQure has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, meaning that its share price is 371% more volatile than the broader market.

uniQure currently has a consensus price target of $42.83, indicating a potential upside of 55.81%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anbio Biotechnology has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Anbio Biotechnology's return on equity of 0.00% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Anbio Biotechnology	N/A	N/A	N/A

Anbio Biotechnology has lower revenue, but higher earnings than uniQure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$18.09M	95.82	-$198.97M	-$3.48	N/A
Anbio Biotechnology	$8.65M	424.84	$6.40M	N/A	N/A

In the previous week, uniQure had 12 more articles in the media than Anbio Biotechnology. MarketBeat recorded 14 mentions for uniQure and 2 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.19 beat uniQure's score of 0.52 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anbio Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

uniQure and Anbio Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QURE vs. The Competition

Export

Metric	uniQure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.73B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-7.88	18.77	20.85	25.56
Price / Sales	95.82	263.59	543.57	72.25
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	11.60	6.77	9.87	6.72
Net Income	-$198.97M	$24.11M	$3.55B	$333.62M
7 Day Performance	13.83%	0.17%	-0.23%	0.35%
1 Month Performance	60.85%	0.98%	1.47%	4.00%
1 Year Performance	117.31%	78.11%	41.05%	36.32%

uniQure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	2.9275 of 5 stars	$27.75 -4.9%	$42.83 +54.4%	+127.7%	$1.75B	$18.09M	N/A	500	Insider Trade
DNTH Dianthus Therapeutics	3.083 of 5 stars	$87.42 -0.4%	$115.55 +32.2%	+355.1%	$4.78B	$2.04M	N/A	80	Positive News
INDV Indivior	3.7624 of 5 stars	$37.66 +2.4%	$39.33 +4.4%	+242.7%	$4.48B	$1.24B	22.96	1,051	Positive News
LEGN Legend Biotech	3.9319 of 5 stars	$23.59 +0.3%	$58.31 +147.2%	-7.8%	$4.35B	$1.03B	N/A	2,965	Earnings Report Analyst Forecast
KNSA Kiniksa Pharmaceuticals International	3.425 of 5 stars	$55.27 +2.8%	$60.86 +10.1%	+130.9%	$4.12B	$677.56M	61.41	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QURE) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

uniQure (QURE) Competitors

QURE vs. DNTH, INDV, LEGN, KNSA, and NNNN

How does uniQure compare to Dianthus Therapeutics?

Summary

How does uniQure compare to Indivior?

Summary

How does uniQure compare to Legend Biotech?

Summary

How does uniQure compare to Kiniksa Pharmaceuticals International?

Summary

How does uniQure compare to Anbio Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

uniQure (QURE) Competitors

QURE vs. DNTH, INDV, LEGN, KNSA, and NNNN

How does uniQure compare to Dianthus Therapeutics?

Do insiders & institutionals hold more shares of DNTH or QURE?

Which has more risk & volatility, DNTH or QURE?

Is DNTH or QURE more profitable?

Does the media refer more to DNTH or QURE?

Do analysts rate DNTH or QURE?

Which has higher earnings & valuation, DNTH or QURE?

Summary

How does uniQure compare to Indivior?

Do institutionals & insiders hold more shares of INDV or QURE?

Which has more volatility & risk, INDV or QURE?

Is INDV or QURE more profitable?

Does the media prefer INDV or QURE?

Do analysts recommend INDV or QURE?

Which has better valuation & earnings, INDV or QURE?

Summary

How does uniQure compare to Legend Biotech?

Which has more risk & volatility, QURE or LEGN?

Which has preferable valuation and earnings, QURE or LEGN?

Do analysts prefer QURE or LEGN?

Do insiders and institutionals believe in QURE or LEGN?

Is QURE or LEGN more profitable?

Does the media favor QURE or LEGN?

Summary

How does uniQure compare to Kiniksa Pharmaceuticals International?

Which has more risk and volatility, QURE or KNSA?

Does the media favor QURE or KNSA?

Which has higher valuation & earnings, QURE or KNSA?

Do analysts prefer QURE or KNSA?

Is QURE or KNSA more profitable?

Do institutionals and insiders believe in QURE or KNSA?

Summary

How does uniQure compare to Anbio Biotechnology?

Do institutionals and insiders believe in QURE or NNNN?

Which has more risk and volatility, QURE or NNNN?

Do analysts prefer QURE or NNNN?

Is QURE or NNNN more profitable?

Which has higher valuation & earnings, QURE or NNNN?

Does the media favor QURE or NNNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools